Targets of treatment in the acute phase of cerebral infarction

Kortaro Tanaka, Yasuo Fukuuchi, Shigeru Nogawa, Daisuke Ito, Shigeaki Suzuki, Tomohisa Dembo, Arifumi Kosakai

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

In the acute phase of cerebral infarction, many experimental data suggest that free radicals including superoxide, hydroxy radical and nitric oxide are one of the most important factors to cause brain damage. We have clearly detected nitrotyrosine (a marker of endogenous production of peroxynitrite, which is readily produced from superoxide and nitric oxide) in neurons and intraparenchymal vascular walls during post-ischemic reperfusion. Free radical scavengers thus seem to be very promising tools of treatment, and one of them (edaravone) has recently been approved for clinical use in Japan. CREB (cyclic AMP response element binding protein) is a DNA-binding transcription factor, and its function is activated by phosphorylation of Ser133 residue. CREB plays important roles in neuronal development, synaptic plasticity and regeneration. We have found that phosphorylation of CREB is significantly and persistently increased in surviving neurons and oligodendrocytes in post-ischemic brain, while this phosphorylation is only transiently increased in neurons and oligodendrocytes which eventually die. These data suggest that CREB phosphorylation plays an important role in protection of ischemic brain tissue. Oligodendrocyte progenitor cells (OPC) remain abundant throughout the adult brain, and retain their ability to become not only mature oligodendrocytes, but also neurons. We have recently found that OPC are significantly activated and proliferate in the peri-infarct area at 1-2 weeks after ischemia, suggesting that OPC may be involved in the repair mechanisms of ischemic brain. Future targets of stroke treatment should include enhancement of intrinsic protection mechanisms such as CREB phosphorylation and activation of progenitors cells.

Original languageEnglish
Pages (from-to)1052-1054
Number of pages3
JournalClinical Neurology
Volume41
Issue number12
Publication statusPublished - 2001 Dec 1

Fingerprint

Oligodendroglia
Cerebral Infarction
Cyclic AMP Response Element-Binding Protein
Phosphorylation
Stem Cells
Brain
Neurons
Superoxides
Nitric Oxide
Free Radical Scavengers
Neuronal Plasticity
Peroxynitrous Acid
Reperfusion
Free Radicals
Blood Vessels
Regeneration
Japan
Transcription Factors
Ischemia
Stroke

Keywords

  • Cerebral infarction
  • CREB
  • Free radical
  • Oligodendrocyte progenitor cells
  • Treatment

ASJC Scopus subject areas

  • Clinical Neurology

Cite this

Tanaka, K., Fukuuchi, Y., Nogawa, S., Ito, D., Suzuki, S., Dembo, T., & Kosakai, A. (2001). Targets of treatment in the acute phase of cerebral infarction. Clinical Neurology, 41(12), 1052-1054.

Targets of treatment in the acute phase of cerebral infarction. / Tanaka, Kortaro; Fukuuchi, Yasuo; Nogawa, Shigeru; Ito, Daisuke; Suzuki, Shigeaki; Dembo, Tomohisa; Kosakai, Arifumi.

In: Clinical Neurology, Vol. 41, No. 12, 01.12.2001, p. 1052-1054.

Research output: Contribution to journalArticle

Tanaka, K, Fukuuchi, Y, Nogawa, S, Ito, D, Suzuki, S, Dembo, T & Kosakai, A 2001, 'Targets of treatment in the acute phase of cerebral infarction', Clinical Neurology, vol. 41, no. 12, pp. 1052-1054.
Tanaka K, Fukuuchi Y, Nogawa S, Ito D, Suzuki S, Dembo T et al. Targets of treatment in the acute phase of cerebral infarction. Clinical Neurology. 2001 Dec 1;41(12):1052-1054.
Tanaka, Kortaro ; Fukuuchi, Yasuo ; Nogawa, Shigeru ; Ito, Daisuke ; Suzuki, Shigeaki ; Dembo, Tomohisa ; Kosakai, Arifumi. / Targets of treatment in the acute phase of cerebral infarction. In: Clinical Neurology. 2001 ; Vol. 41, No. 12. pp. 1052-1054.
@article{c00c4e3af69d4431b736066612722972,
title = "Targets of treatment in the acute phase of cerebral infarction",
abstract = "In the acute phase of cerebral infarction, many experimental data suggest that free radicals including superoxide, hydroxy radical and nitric oxide are one of the most important factors to cause brain damage. We have clearly detected nitrotyrosine (a marker of endogenous production of peroxynitrite, which is readily produced from superoxide and nitric oxide) in neurons and intraparenchymal vascular walls during post-ischemic reperfusion. Free radical scavengers thus seem to be very promising tools of treatment, and one of them (edaravone) has recently been approved for clinical use in Japan. CREB (cyclic AMP response element binding protein) is a DNA-binding transcription factor, and its function is activated by phosphorylation of Ser133 residue. CREB plays important roles in neuronal development, synaptic plasticity and regeneration. We have found that phosphorylation of CREB is significantly and persistently increased in surviving neurons and oligodendrocytes in post-ischemic brain, while this phosphorylation is only transiently increased in neurons and oligodendrocytes which eventually die. These data suggest that CREB phosphorylation plays an important role in protection of ischemic brain tissue. Oligodendrocyte progenitor cells (OPC) remain abundant throughout the adult brain, and retain their ability to become not only mature oligodendrocytes, but also neurons. We have recently found that OPC are significantly activated and proliferate in the peri-infarct area at 1-2 weeks after ischemia, suggesting that OPC may be involved in the repair mechanisms of ischemic brain. Future targets of stroke treatment should include enhancement of intrinsic protection mechanisms such as CREB phosphorylation and activation of progenitors cells.",
keywords = "Cerebral infarction, CREB, Free radical, Oligodendrocyte progenitor cells, Treatment",
author = "Kortaro Tanaka and Yasuo Fukuuchi and Shigeru Nogawa and Daisuke Ito and Shigeaki Suzuki and Tomohisa Dembo and Arifumi Kosakai",
year = "2001",
month = "12",
day = "1",
language = "English",
volume = "41",
pages = "1052--1054",
journal = "Clinical Neurology",
issn = "0009-918X",
publisher = "Societas Neurologica Japonica",
number = "12",

}

TY - JOUR

T1 - Targets of treatment in the acute phase of cerebral infarction

AU - Tanaka, Kortaro

AU - Fukuuchi, Yasuo

AU - Nogawa, Shigeru

AU - Ito, Daisuke

AU - Suzuki, Shigeaki

AU - Dembo, Tomohisa

AU - Kosakai, Arifumi

PY - 2001/12/1

Y1 - 2001/12/1

N2 - In the acute phase of cerebral infarction, many experimental data suggest that free radicals including superoxide, hydroxy radical and nitric oxide are one of the most important factors to cause brain damage. We have clearly detected nitrotyrosine (a marker of endogenous production of peroxynitrite, which is readily produced from superoxide and nitric oxide) in neurons and intraparenchymal vascular walls during post-ischemic reperfusion. Free radical scavengers thus seem to be very promising tools of treatment, and one of them (edaravone) has recently been approved for clinical use in Japan. CREB (cyclic AMP response element binding protein) is a DNA-binding transcription factor, and its function is activated by phosphorylation of Ser133 residue. CREB plays important roles in neuronal development, synaptic plasticity and regeneration. We have found that phosphorylation of CREB is significantly and persistently increased in surviving neurons and oligodendrocytes in post-ischemic brain, while this phosphorylation is only transiently increased in neurons and oligodendrocytes which eventually die. These data suggest that CREB phosphorylation plays an important role in protection of ischemic brain tissue. Oligodendrocyte progenitor cells (OPC) remain abundant throughout the adult brain, and retain their ability to become not only mature oligodendrocytes, but also neurons. We have recently found that OPC are significantly activated and proliferate in the peri-infarct area at 1-2 weeks after ischemia, suggesting that OPC may be involved in the repair mechanisms of ischemic brain. Future targets of stroke treatment should include enhancement of intrinsic protection mechanisms such as CREB phosphorylation and activation of progenitors cells.

AB - In the acute phase of cerebral infarction, many experimental data suggest that free radicals including superoxide, hydroxy radical and nitric oxide are one of the most important factors to cause brain damage. We have clearly detected nitrotyrosine (a marker of endogenous production of peroxynitrite, which is readily produced from superoxide and nitric oxide) in neurons and intraparenchymal vascular walls during post-ischemic reperfusion. Free radical scavengers thus seem to be very promising tools of treatment, and one of them (edaravone) has recently been approved for clinical use in Japan. CREB (cyclic AMP response element binding protein) is a DNA-binding transcription factor, and its function is activated by phosphorylation of Ser133 residue. CREB plays important roles in neuronal development, synaptic plasticity and regeneration. We have found that phosphorylation of CREB is significantly and persistently increased in surviving neurons and oligodendrocytes in post-ischemic brain, while this phosphorylation is only transiently increased in neurons and oligodendrocytes which eventually die. These data suggest that CREB phosphorylation plays an important role in protection of ischemic brain tissue. Oligodendrocyte progenitor cells (OPC) remain abundant throughout the adult brain, and retain their ability to become not only mature oligodendrocytes, but also neurons. We have recently found that OPC are significantly activated and proliferate in the peri-infarct area at 1-2 weeks after ischemia, suggesting that OPC may be involved in the repair mechanisms of ischemic brain. Future targets of stroke treatment should include enhancement of intrinsic protection mechanisms such as CREB phosphorylation and activation of progenitors cells.

KW - Cerebral infarction

KW - CREB

KW - Free radical

KW - Oligodendrocyte progenitor cells

KW - Treatment

UR - http://www.scopus.com/inward/record.url?scp=0035761488&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0035761488&partnerID=8YFLogxK

M3 - Article

C2 - 12235793

AN - SCOPUS:0035761488

VL - 41

SP - 1052

EP - 1054

JO - Clinical Neurology

JF - Clinical Neurology

SN - 0009-918X

IS - 12

ER -